[A clinical evaluation of SY5555 in the treatment of pediatric infections].

Abstract

1. SY5555 dry syrup (powder which is dissolved before use) was administered to 25 patients with bacterial infections (6 cases of bronchitis, 2 cases of bronchopneumonia, 1 case of pertussis, 3 cases of scarlet fever, 5 cases of tonsillitis, 3 cases of urinary tract infections, 2 cases of staphylococcal scalded skin syndrome, 1 case of impetigo, 2 cases of purulent lymphadenitis). 2. Clinical efficacies were excellent in 11 patients and good in 13, poor in 1 with an efficacy rate of 96.0%. As pathogenic organisms, 15 strains were identified and 14 of them were eradicated with eradication rate of 93.3%. 3. No side effects were observed. As for abnormal laboratory test results increase in eosinophiles in 2 cases, decrease in filamented neutrophiles in 1 case, elevation of GOT and GTP in 1 case and elevation of GPT and gamma-GTP were observed. 4. There was no rejection incidence of the drug during the therapy. From the above results, we consider SY5555 in dry syrup form to be a useful and safe drug in the treatment of various bacterial infections in pediatric patients.

• Authors: S Furukawa, T Okada
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 48 Issue 2 Pg. 210-9 (Feb 1995) ISSN: 0368-2781 [Print] Japan
• PMID: 7745811 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Carbapenems
• SUN 5555

Topics

• Administration, Oral
• Bacteria (drug effects, isolation & purification)
• Bacterial Infections (drug therapy, microbiology)
• Carbapenems (administration & dosage, pharmacology)
• Child
• Child, Preschool
• Drug Resistance, Microbial
• Female
• Humans
• Infant
• Male